Pipelines

Side Navigation

R&D

Pipelines

  • Home
  • R&D
  • Pipelines
Small molecule
  • Anti-HIV-1/AIDS inhibitor: AVI-CO-004
    AVI-CO-004 is a new and novel drug candidate for the treatment against HIV/AIDS with a novel mode of action that might also overcome HIV drug resistance problems. It is currently in Phase 1 clinical trial.
Peptides/Biologics
  • Anti-HIV Peptide
    Anti-HIV Peptide, which had been discovered and developed by Avixgen, is not only able to block the production of HIV, but also equipped with a property of cell penetrating. This property can overcome drug delivery issues and maximize the drug efficacy. Currently, it is in a Preclinical stage of development.
  • Anti-Cancer Peptide
    Anti-Cancer Peptide, which has been discovered and developed by Avixgen, prevents the growth of cancer cells through blocking of angiogenesis. Thus, it can also be applied to various therapeutic areas that involve anti-angiogenesis process. It is currently in a Preclinical stage of development.
  • Novel CPP based new drugs and therapeutics
    Based on a novel CPP(Cell Penetrating Peptide) we have discovered and developed at Avixgen, we are selectively developing numerous promising therapeutic molecules which then break through the problem of delivery issues associated with them. These include fusion proteins for autoimmune disease and various medical indications, which are currently in development and are being studied as potentially novel therapies in the field.